Fewer Proprietary Drug Names Rejected With FDA, Industry On Same Page
This article was originally published in The Tan Sheet
After several false starts, FDA and the pharma industry appear to be on the same page about vetting potential brand names for new drugs. FDA’s rate of rejecting proposed brand names has dropped from 50% or higher when the decade began to about 25%, according to Office of Surveillance and Epidemiology data.
You may also be interested in...
The trade group recommends FDA write a separate proprietary name guidance for OTC drugs. FDA’s draft guidance also renders useless OTC manufacturers’ expertise in conducting tests to determine whether consumers safely self-select nonprescription drugs based on labeling, CHPA says in comments.
US House of Representatives if moving forward with a bill to respond to advocacy from ALS patients for more attention from FDA. The bill focuses on planning and scientific support, not new pathways.
Participants in a US FDA meeting on opioid REMS did not treat a move to mandatory education as a foregone conclusion. Instead, they delved frequently into alternate approaches to enhance the education itself.